Intercept Pharmaceuticals - Stock Price History | ICPT

Historical daily share price chart and data for Intercept Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for Intercept Pharmaceuticals as of September 27, 2021 is 16.27.
  • The all-time high Intercept Pharmaceuticals stock closing price was 462.26 on March 14, 2014.
  • The Intercept Pharmaceuticals 52-week high stock price is 43.16, which is 165.3% above the current share price.
  • The Intercept Pharmaceuticals 52-week low stock price is 11.60, which is 28.7% below the current share price.
  • The average Intercept Pharmaceuticals stock price for the last 52 weeks is 24.36.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Intercept Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 61.2651 118.6800 118.6800 24.4800 24.7000 -80.07%
2019 88.6156 97.2500 124.1000 57.3600 123.9200 22.95%
2018 85.8934 56.3500 127.5500 52.7200 100.7900 72.53%
2017 100.7735 102.9500 135.0300 57.0100 58.4200 -46.23%
2016 135.5061 147.8200 173.0300 93.7100 108.6500 -27.25%
2015 217.8551 159.4900 313.9800 139.6800 149.3500 -4.26%
2014 259.2309 68.7700 462.2600 67.7700 156.0000 128.47%
2013 44.6674 34.2600 76.8200 31.0800 68.2800 99.42%
2012 24.4733 19.4000 34.9000 18.0600 34.2400 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.540B $0.313B
Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29